News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Insider Information

Epigenomics AG issues EUR 500,000 in convertible bonds to YA Global Master SPV Ltd.

PDF 84 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516, OTC: EPGNY) announces that upon registration of the conditional capital of the Company today successfully completed the issuance of convertible bonds with a nominal amount of EUR 500,000. These convertible bonds constitute the first tranche of a total issuance of up to EUR 5m […]

Read more

Ad hoc: Epigenomics AG secures financing of up to EUR 5m

PDF 80 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that it has entered into an agreement with YA Global Master SPV Ltd. through which it secured a convertible bond financing for up to EUR 5m. Under the terms of the agreement, YA Global Master SPV Ltd., over a period of up to […]

Read more

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

PDF 76 KB   Not for distribution in the United States Berlin, Germany – The Executive Board of Epigenomics AG (ISIN: E000A1K0516) notifies that during the preparation of the annual financial statements pursuant to German GAAP (HGB) accounting, according to its best judgment a cumulative loss of more than half of the nominal share capital […]

Read more

Ad hoc: Epigenomics AG Reports Non-Inferiority of Blood-based Epi proColon® against Fecal Immunochemical Testing in Detection of Colorectal Cancer in a Head-to-Head Comparative Study

PDF 85 KB   Berlin, Germany, December 04, 2012 – Epigenomics AG (ISIN: DE000A1K0516) announces top-line results from a head-to-head comparative study between its blood-based colorectal cancer (CRC) detection test Epi proColon® and fecal immunochemical testing (FIT) to demonstrate the non-inferiority of Epi proColon® in detection of CRC. In the reported trial, Epi proColon® detected […]

Read more

Ad hoc: Epigenomics AG announces changes in its Executive Management Board

PDF 85 KB   Berlin, Germany, September 25, 2012 – The Supervisory Board of Epigenomics AG (ISIN: DE000A1K0516) and its current CEO Geert Walter Nygaard today agreed that Mr. Nygaard will leave the Executive Management Board of the company effective 30 September 2012. The current CFO, Dr. Thomas Taapken, thereby becomes the sole Executive Board […]

Read more

Ad hoc: Epigenomics AG Plans Changes in the Composition and Size of its Supervisory Board

PDF 158 KB   Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) today decided to propose to the shareholders of the company at the upcoming Annual General Meeting on May 2, 2012 to vote in favor of a reduction of the size of the Supervisory Board from currently six to three members. Furthermore, the company’s Chairman, […]

Read more